Granahan Investment Management LLC Sells 248,251 Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO)

Granahan Investment Management LLC lowered its stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 13.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,617,178 shares of the medical instruments supplier’s stock after selling 248,251 shares during the quarter. Granahan Investment Management LLC owned about 3.71% of Harvard Bioscience worth $3,412,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in HBIO. Focus Partners Wealth bought a new stake in Harvard Bioscience in the 4th quarter valued at approximately $28,000. Intech Investment Management LLC bought a new stake in shares of Harvard Bioscience in the fourth quarter worth $35,000. Sei Investments Co. bought a new stake in shares of Harvard Bioscience in the fourth quarter worth $47,000. Jane Street Group LLC boosted its holdings in Harvard Bioscience by 55.5% during the fourth quarter. Jane Street Group LLC now owns 35,769 shares of the medical instruments supplier’s stock worth $75,000 after purchasing an additional 12,767 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Harvard Bioscience by 63.0% during the third quarter. JPMorgan Chase & Co. now owns 29,501 shares of the medical instruments supplier’s stock worth $79,000 after purchasing an additional 11,397 shares during the last quarter. Institutional investors and hedge funds own 80.87% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on HBIO. Benchmark cut their price target on shares of Harvard Bioscience from $5.50 to $4.50 and set a “speculative buy” rating on the stock in a research report on Monday, March 24th. KeyCorp reiterated a “sector weight” rating on shares of Harvard Bioscience in a report on Wednesday, April 9th. Finally, StockNews.com assumed coverage on Harvard Bioscience in a research note on Tuesday, May 6th. They issued a “hold” rating for the company.

Harvard Bioscience Stock Performance

NASDAQ HBIO opened at $0.32 on Friday. The firm’s fifty day moving average price is $0.50 and its two-hundred day moving average price is $1.43. Harvard Bioscience, Inc. has a 1 year low of $0.29 and a 1 year high of $3.60. The firm has a market capitalization of $14.15 million, a P/E ratio of -0.97 and a beta of 1.44. The company has a current ratio of 2.06, a quick ratio of 0.91 and a debt-to-equity ratio of 0.52.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.